Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCC trial in older adults with metastatic colorectal cancer
ACTRN12618000233224Phase 2Terminated
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival rate at 6 months. Started Jul 2018; status: terminated.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ACTRN12618000233224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000233224.